Compare SN & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SN | INSM |
|---|---|---|
| Founded | 1993 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 22.4B |
| IPO Year | 2023 | 2000 |
| Metric | SN | INSM |
|---|---|---|
| Price | $177.88 | $125.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 24 |
| Target Price | $133.13 | ★ $201.17 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.77 | N/A |
| Revenue | ★ $6,399,188,000.00 | N/A |
| Revenue This Year | $15.22 | $182.31 |
| Revenue Next Year | $10.74 | $65.19 |
| P/E Ratio | $97.95 | ★ N/A |
| Revenue Growth | ★ 15.75 | N/A |
| 52 Week Low | $83.12 | $90.39 |
| 52 Week High | $194.54 | $212.75 |
| Indicator | SN | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 55.71 |
| Support Level | $142.57 | $122.21 |
| Resistance Level | $192.88 | $137.70 |
| Average True Range (ATR) | 5.73 | 4.07 |
| MACD | -2.63 | -0.53 |
| Stochastic Oscillator | 27.54 | 58.35 |
SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment, and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The Company has identified two operating segments, Domestic and International. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.